Jefferson urologist Leonard Gomella, MD, chair of the Department of Urology and director of clinical affairs at Jefferson’s Kimmel Cancer Center, discusses new data on from a phase IV clinical data on the use of the dendritic cell vaccine sipuleucel-T – Provenge – in men with castration-resistant prostate cancer on OncLive.
Data from the post-market PROCEED registry was presented at the 2014 Genitourinary Cancer Symposium in San Francisco. The registry was established to gather additional information on patient survival and on the risk of ‘cerebrovascular events’ in men who received Provenge.
“I think the interest in it is slowly growing,” Dr. Gomella explains. “I think there are more people saying sipuleucel-T is a viable option for metastatic castrate resistant prostate cancer.”
Check out Dr. Gomella in the video below:
Or read the story on the OncLive website